We use cookies to improve your experience. See our Privacy Policy.
aTYR PHARMA INC is a biological products, (no diagnostic substances) company incorporated in DE, trading on the Nasdaq.
Brefyr has analyzed 2 SEC filings for ATYR, with the most recent being a 8-K filed on November 6, 2026. Each filing is scored for significance on a 1-10 scale to help investors quickly identify the most important disclosures.
Exchange
Nasdaq
Sector
Healthcare
Filer Category
Non-accelerated filer<br>Smaller reporting company
Fiscal Year End
December
aTYR PHARMA INC is a biological products, (no diagnostic substances) company incorporated in DE, trading on the Nasdaq.
Brefyr has analyzed 2 SEC filings for ATYR, including 8-K, 10-Q. The most recent filing was a 8-K filed on November 6, 2026.
No recent insider transactions have been detected in ATYR SEC filings.
aTYR PHARMA INC is incorporated in DE and is classified as a Non-accelerated filer<br>Smaller reporting company filer with the SEC.
aTYR PHARMA INC's fiscal year ends in December. Annual 10-K reports are typically filed within 60-90 days after the fiscal year end.
Last updated: November 6, 2026
Data sourced from SEC EDGAR public filings. For informational purposes only — not investment advice. AI-generated summaries may contain errors. See our full disclaimer.